Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

被引：0
|
作者：
Leslie, K. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sill, M. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Darcy, K. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Baron, A. T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wilken, J. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Godwin, A. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Cook, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, J. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Maihle, N. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ Iowa, Albuquerque, NM USA
[3] Gynecol Oncol Grp, Stat Off, Buffalo, NY USA
[4] Univ Kentucky, Lexington, KY USA
[5] Yale Univ, New Haven, CT USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Indiana Univ, Bloomington, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Schilder, RJ
    Blessing, JA
    Pearl, ML
    Rose, PG
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 343 - 349
  • [32] Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Burger, Robert A.
    Deng, Wei
    Makker, Vicky
    Collins, Yvonne
    Gray, Heidi
    Debernardo, Robert
    Martin, Lainie P.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 466 - 470
  • [33] PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    SLAYTON, RE
    BLESSING, JA
    DELGADO, G
    CANCER TREATMENT REPORTS, 1982, 66 (08): : 1669 - 1671
  • [34] PHASE-II TRIAL OF PIPERAZINEDIONE IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    THIGPEN, JT
    BLESSING, JA
    HOMESLEY, HD
    PETTY, W
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 21 - 23
  • [35] PHASE-II TRIAL OF ADRIAMYCIN IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - GYNECOLOGIC ONCOLOGY GROUP-STUDY
    THIGPEN, JT
    BUCHSBAUM, HJ
    MANGAN, C
    BLESSING, JA
    CANCER TREATMENT REPORTS, 1979, 63 (01): : 21 - 27
  • [36] Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
    Monk, Bradley J.
    Sill, Michael W.
    Burger, Robert A.
    Gray, Heidi J.
    Buekers, Thomas E.
    Roman, Lynda D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1069 - 1074
  • [37] Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study
    Matei, D.
    Sill, M. W.
    DeGeest, K.
    Bristow, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)
    Post, C. C. B.
    Westermann, A. M.
    Boere, I. A.
    Witteveen, P. O.
    Ottevanger, P. B.
    Sonke, G. S.
    Lalisang, R., I
    Putter, H.
    Kranenbarg, E. Meershoek-Klein
    Braak, J. P. B. M.
    Creutzberg, C. L.
    Bosse, T.
    Kroep, J. R.
    GYNECOLOGIC ONCOLOGY, 2022, 165 (02) : 223 - 229
  • [39] Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
    Randall, Leslie M.
    Sill, Michael W.
    Burger, Robert A.
    Monk, Bradley J.
    Buening, Barbara
    Sorosky, Joel I.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (03) : 563 - 568
  • [40] A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
    Tait, David L.
    Blessing, John A.
    Hoffman, James S.
    Moore, Kathleen N.
    Spirtos, Nick M.
    Lachance, Jason A.
    Rotmensch, Jacob
    Miller, David S.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : 118 - 121
12345